替加环素相关药物性胆汁淤积性肝病的影响因素分析及风险预测模型构建
2025-11-16刘丽娜王建青张伦俞军

中图分类号R969.3 文献标志码A 文章编号 1001-0408(2025)20-2555-06
DOI 10.6039/j.issn.1001-0408.2025.20.12
键词替加环素;药物性胆汁淤积性肝病;药物性肝损伤;影响因素;预测模型
Analysis of influential factors and the construction of arisk prediction model for tigecycline-related druginduced cholestatic liverdisease
LIU Lina,WANG Jianqing,ZHANG Lun,YU Jun[Dept. of Pharmacy,Anhui Public Health Clinical Center (the First Afiliated Hospital of Anhui Medical University North District),Hefei 230012,China]
ABSTRACTOBJECTIVEToanalyze theinfluentialfactorsof drug-inducedcholestaticliverdisease(DIC)relatedto tigecycline(TGC),andestablishapredictionmodelfortheriskofthisadversereactionMETHODSDataof707hospitalized patientswhoreceivedTGCtreatmentinourhospitalfromAugust2022 toAugust2024werecolectedandrandomlydivided into training set ( n=566 )and test set (
)at a ratio of 8:2. Prediction variables were screened using the least absolute shrinkage andselectionoperatorregressionanalysis.MultivariateLogistcregresionanalysiswasusedtoscreentheindependentriskfactos forTGC-relatedDIC,andanomogrampreditionmodelwasdrawnbasedontheabovefactors.Thepredictionperformanceof the model was evaluated bythereceiveroperatorcharacteristiccurve (ROCcurve)anditsarea under thecurve (AUC).Theacuracy
ofthemodel wasassessed bytheHosmer-Lemeshow goodnessof-fittestandcalibration curves.Theclinical netbenefitofthe prediction model were evaluated by decision curve analysis. RESULTS Among the 7O7 patients,93 patients developed DIC,with an incidence rate of 13.15% .Gender,age,highdoseadministration of TGC, intensive care unit(ICU) admission,duration of medication of TGC,and concurrent use of antifungal drug voriconazole were independent risk factors for the occurrence of TGC-related DIC( ⋅Plt;0.05 ).The
AUC of the training set model was 0.745 ( 95%CI : 0.687-0.801),with a sensitivity of 76.6% and a specificity of 60.3% . The AUC of ROC curve of the test set model was 0.762( 95%CI : 0.650-0.900),with a sensitivity of 81.3% and a specificity of 72.0% .The Hosmer-Lemeshow goodness-of-fit test for the training set,the χ2 value was 5.187 and P was 0.737;and for the test set,the χ2 valuewas 9.980 and P was O.266.The mean absolute eror of the calibrationcurve for the training set was O.O12,and for the test set,it was O.O38. The risk threshold range for the training set was 4%-45% ,and for the test set,it was 4%-28% . CONCLUSIONS Age,gender,high-doseadministrationofTGC,ICUadmisson,durationofmedicationofTGC,andconcurrentuseofantifungal drugvoriconazoleareindependentriskfactorsforTGC-relatedDIC.TheestablishedTGC-relatedDICriskpredictionmodelhas good prediction performance and accuracy.
KEYWORDStigecylie;drug-inducedcholestaticliverdisease;drug-inducedliverijury;influentialfactors;predictioodel
替加环素(tigecycline,TGC)是一种四环素类抗菌药物,具有广谱抗菌活性,能抑制耐甲氧西林金黄色葡萄球菌、多重耐药鲍曼不动杆菌和耐万古霉素肠球菌等菌株的生长,已被美国FDA和欧洲药品管理局等批准用于复杂皮肤软组织感染、腹腔内感染及成人社区获得性肺炎等的治疗。随着TGC的广泛使用,其所致不良反应备受临床关注。除常见的胃肠道反应外,TGC相关药物性肝损伤(drug-induced liver injury,DILI)的发生率高达 5.7%~28.9% ,尤以药物性胆汁淤积性肝病(drug-induced cholestasis liver disease,DIC)最为常见[2-3]。DIC是DILI中严重程度最高的类型,可进展为胆管消失综合征和硬化性胆管炎,最终可导致肝纤维化、肝硬化甚至肝功能衰竭。DIC的发生可能与药物诱导的胆管损伤致胆管细胞严重受损有关,一般涉及主要经胆汁排泄的药物4。DIC通常可在停药后数天至数个月内恢复,然而随着患者病程的发展,其病死率可高达 10% 左右[5-]。TGC主要经胆道代谢排出,进入胆汁后,可能通过抑制胆汁盐输出泵功能而诱发DIC。为避免药物不良事件发生、改善患者治疗结局,及时识别和治疗DIC显得尤为重要。尽管自前学界在DIC的机制研究方面取得了一些进展,但其诊断尚无统一的\"金标准”且临床仍缺乏有效的治疗措施[6.8-9],亟须构建TGC相关DIC风险预测模型以协助临床早期识别高风险患者并准确评估其治疗风险及预后。基于此,本研究拟分析TGC相关DIC的影响因素,并建立该不良反应的风险预测模型,以期为TGC相关DIC的防治提供依据。……
